AnaptysBio, a early-stage biotech developing antibodies for severe peanut allergy and asthma, announced terms for its IPO on Tuesday.
The San Diego, CA-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to $16. At the midpoint of the proposed range, AnaptysBio would command a fully diluted market value of $299 million.
AnaptysBio was founded in 2005 and booked $18 million in sales for the 12 months ended September 30, 2016. It plans to list on the Nasdaq under the symbol ANAB. Credit Suisse and Stifel are the joint bookrunners on the deal. A pricing date has not yet been disclosed.
